0001144204-18-023852.txt : 20180430 0001144204-18-023852.hdr.sgml : 20180430 20180430161525 ACCESSION NUMBER: 0001144204-18-023852 CONFORMED SUBMISSION TYPE: NT 20-F PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180430 DATE AS OF CHANGE: 20180430 EFFECTIVENESS DATE: 20180430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SINOVAC BIOTECH LTD CENTRAL INDEX KEY: 0001084201 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: B9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-32371 FILM NUMBER: 18789928 BUSINESS ADDRESS: STREET 1: NO. 15 ZHI TONG ROAD, STREET 2: ZHONGGUANCUN TECH PARK, CHANGPING DISTR. CITY: BEIJING STATE: F4 ZIP: 102200 BUSINESS PHONE: 86-10-82890088 MAIL ADDRESS: STREET 1: NO. 15 ZHI TONG ROAD, STREET 2: ZHONGGUANCUN TECH PARK, CHANGPING DISTR. CITY: BEIJING STATE: F4 ZIP: 102200 FORMER COMPANY: FORMER CONFORMED NAME: NET FORCE SYSTEMS INC DATE OF NAME CHANGE: 19991110 NT 20-F 1 tv492563_nt20f.htm NT 20-F

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

   

   
(Check One)      

¨  Form 10-K     x  Form 20-F     ¨  Form 11-K     ¨  Form 10-Q     ¨  Form 10-D

¨  Form N-SAR     ¨  Form N-CSR 

   
    For Period Ended: December 31, 2017
   
    ¨  Transition Report on Form 10-K
    ¨  Transition Report on Form 20-F
    ¨  Transition Report on Form 11-K
    ¨  Transition Report on Form 10-Q
    ¨  Transition Report on Form N-SAR
   
    For the Transition Period Ended:                                                                  

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:             

 

 

 

PART I — REGISTRANT INFORMATION

 

SINOVAC BIOTECH LTD.
Full Name of Registrant
 
N/A
Former Name if Applicable
 
No. 15 Zhi Tong Road, Zhongguancun Science and Technology Park, Changping District
Address of Principal Executive Office (Street and Number)
 
Beijing 102200, People’s Republic of China
City, State and Zip Code

  

 

 

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

    (a)   The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
¨   (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report or portion thereof, could not be filed within the prescribed time period.

 

On April 17, 2018, Aihua Pan, the Chairman of the Board of the Company’s 73.09% controlled China subsidiary, Sinovac Biotech Co., Ltd., appointed by Sinobioway Biomedicine Co., Ltd., the minority shareholder of Sinovac Beijing, and dozens of unnamed individuals forcibly entered Sinovac Beijing’s corporate offices and limited the physical movement of the employees in Sinovac Beijing’s general manager’s office and finance department. One of the Company’s buildings where the finance department is located is occupied and employees of Sinovac Beijing are not permitted to enter. The occupation of the finance department of Sinovac Beijing has caused disruption to the Company’s 2017 annual audit, which will delay the filing of the Company’s 2017 Annual Report.

 

 

 

PART IV — OTHER INFORMATION

 

(1)Name and telephone number of person to contact in regard to this notification
  
 Helen Yang   +86   1860-095-1379  
 (Name)   (Area Code)   (Telephone Number)  

 

(2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).    Yes  x    No  ¨
  
  

 

(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?    Yes  ¨    No  x

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 

SINOVAC BIOTECH LTD.

 

(Name of Registrant as specified in charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:     April 30, 2018   By:     /s/ Nan Wang  
           

Name: Nan Wang

Title: Chief Financial Officer